Compare and Contrast: Defining the Value of Diagnostic Imaging Agents for MRI – CE

This enduring monograph provides technologists, imaging nurses, and administrators with an evidence-based review of gadolinium-based contrast agents (GBCAs) used in magnetic resonance imaging, with emphasis on differences in relaxivity, dosing, safety profiles, and clinical performance. The activity supports imaging professionals involved in patient care and contrast administration by highlighting how contrast agent selection can impact diagnostic quality, patient exposure to gadolinium, and overall value of care.

At the completion of this activity, the participant will be able to:

1. Describe the key differences among gadolinium-based contrast agents (GBCAs), including molecular structure, relaxivity, dosing, and safety profiles that influence MRI diagnostic performance.
2. Explain how GBCA selection impacts patient safety, including considerations related to gadolinium exposure, renal function, and use in patients requiring repeated contrast-enhanced MRI examinations.
3. Discuss the role of the pharmacist in evaluating MRI contrast agents for formulary inclusion, including considerations of efficacy, safety, sustainability, and overall value within health-system practice.

The content of this CE  webinar is intended for Technologists, Imaging Nurses, Administrators, Researchers, and other healthcare professionals.

This program has been approved for 1.0 hour of Category A CE credit as designated by the International Society for MR Radiographers & Technologists (ISMRT) RCEEM. Additionally, this activity may be available in multiple formats or from different sponsors. ARRT regulations state that an individual may not repeat an activity for credit if it was reported in the same or any subsequent biennium.

Release Date: 01/23/2026 | Expiration Date 01/23/2027

Faculty and Planner Disclosures:
As an accredited provider of continuing medical education, Northwest Imaging Forums, Inc. (NWIF) ensures balance, independence, objectivity, and scientific rigor in all its educational activities. In accordance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education, all faculty and planners are required to disclose all financial relationships with ineligible companies within the last 24 months. All relevant financial relationships have been mitigated by NWIF to ensure the integrity of the CME activity. The planner has nothing to disclose.